本用户的索取資料要求（約有13項）
Dear Sir/ Madam,
Thank you for your email dated 18 November 2022. After consulting the
relevant subject division, please find our reply as foll...
Dear Sir/ Madam,
Thank you for your email dated 10 November 2022. After consulting the
relevant subject division, please find our reply as foll...
Dear Sir/ Madam,
Thank you for your email dated 7 November 2022. After consulting the
relevant subject divisions, please find our reply as foll...
Dear Sir/ Madam,
Thank you for your email dated 14 October 2022. After consulting the
relevant subject division, please find our reply as follows:...
敬啟者:
(本署編號：DO EC 2037/22)
就你於2022年10月17日的電郵查詢，衞生署現回覆如下：
政府參考衞生署衞生防護中心轄下的疫苗可預防疾病科學委員會和新發現及動物傳染
病科學委員會（聯合科學委員會）早前的建議並已購買第三代猴痘疫苗。首批第三代
疫苗（...
Dear Sir/ Madam,
Thank you for your email dated 7 August 2022. After consulting the
relevant subject division, please find our reply as follows...
Dear Sir/ Madam,
Thank you for your email dated 15 July 2022. After consulting the
relevant subject divisions, please find the requested inform...
Dear Sir/Madam,
Further to my reply dated 23 June 2022, please find below the outcome of
the Hospital Authority (HA) Head Office’s review of the...
敬啟者：
(本署編號：DO EC 1186/22)
就你於2022年6月17日的電郵查詢，衞生署現回覆如下：
本署得悉有天花疫苗(Jynneo)獲海外藥物監管機構許可用於預防猴痘感染，因此正積
極向相關藥廠查詢及商討有關疫苗的供應情況。根據「公開資料守則」第1.14段，《...
Dear Sir/ Madam,
Thank you for your email dated 2 June 2022. After consulting the relevant
subject divisions, please find our reply as follows:...
Dear Sir/ Madam,
Thank you for your email dated 29 April 2022. We refer to your request
for information in relation to the disciplinary actions...
Dear Sir/ Madam,
Thank you for your email dated 11 May 2022. After consulting the relevant
subject division, please find our reply as follows: ...
Dear Sir/ Madam,
Thank you for your email dated 29 April 2022. After consulting the
relevant subject division, please find our reply as follows...
本用户的備註
None made.
